Clinical trials: Liver Tumour
Critical Illness, Chronic Disease
Improving Communication About Serious Illness
The purpose of this study is to improve care delivered to patients with serious illness by enhancing communication among patients, families, and clinicians in the outpatient setting.
- Conditions
- Critical Illness, Chronic Disease, Terminal Care, Palliative Care
- Trial name
- ICSI (NCT01933789)
- Testing
- Communication Feedback Form for Patients with Serious Illness
- Where
- 6 sites in United States
- Volunteers
- 817 people
- Sponsor
- University of Washington
Hepatocellular Carcinoma
Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma
The purpose of this study is to establish molecular subtyping of HCC.
- Trial name
- NCT03668158
- Volunteers
- 500 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer
NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC
This study will evaluate nivolumab and ipilimumab, two immunotherapy medicines, given before repeat liver surgery in adults whose liver cancer (hepatocellular carcinoma) has returned within the liver after previous surgery.
- Trial name
- CA209-1594 (NCT07919717)
- Testing
- Nivolumab, Ipilimumab, Repeat Hepatectomy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
CRC (Colorectal Cancer), Liver Metastases From Colorectal Primary Cancer
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases
This study focuses on patients with colorectal cancer undergoing surgery for the primary tumor and/or liver metastases. Tumor samples collected during surgery will be used to generate patient-derived models (primary cultures…
- Trial name
- AIRC_ IG 34634 (NCT07497789)
- Volunteers
- 156 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Cancer, Advanced Hepatocellular Carcinoma
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
The main purpose of the study is to establish a safe dose of AZD8055 in patients with mild or moderate liver disease by providing information on any potential side effects this drug may cause and collecting data about how…
- Trial name
- NCT00999882
- Testing
- AZD8055
- Where
- 3 sites in Hong Kong, South Korea
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Changing Trends in HCC Procedures
In France, as in most countries, the incidence of primary liver cancer has increased significantly since the 1980s. In the United States, a study estimating cancer incidence and mortality rates in the coming years predicts that…
- Trial name
- NCT04163627
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Montpellier
Hepatocellular Carcinoma
A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma
The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected hepatocellular carcinoma.
- Trial name
- NCT04635527
- Testing
- IBI318, cTACE
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Melanoma (Skin) Stage IV
Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial
To explore the efficacy and safety of cryoablation combined with hepatic arterial infusion of iparomlimab and tuvonralimab, intravenous dacarbazine, and oral lenvatinib in patients with liver metastases from malignant melanoma.
- Trial name
- Cryo-IA-Check (NCT07847359)
- Testing
- Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Pancreatic Cancer
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and…
- Trial name
- NCT06307080
- Testing
- Multi-mode thermal ablation device, Intravenous anti-PD-1 and chemotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hepatocellular Carcinoma, Liver Cirrhosis
Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Transplantation
This study is a prospective observational study that analyzes the incidence of postoperative delirium in patients undergoing liver transplantation, based on the use of the inhalational anesthetic sevoflurane and the intravenous…
- Trial name
- NCT06767579
- Where
- South Korea
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Hepatocellular Carcinoma
Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC
The aim of this study is to collect data on efficacy and tolerability on a large series of patient of different Italian hospitals in order to support the validation of LifePearl with robust and consistent clinical evidence.
- Trial name
- LIFDOX (NCT03734068)
- Testing
- Chemoembolization Using LifePearl, Doxorubicin
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- International Group of Endovascular Oncology
Malignant Solid Tumour, Liver Metastases
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
A pharmacodynamic study to evaluate the effect of AV-299 on exploratory pharmacodynamic markers in subjects with advanced solid tumors who have liver metastases.
- Trial name
- NCT00969410
- Testing
- AV-299
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Colorectal Cancer
Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer
A prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer Prospective collection of tissues to explore potential biomarkers in blood and/or primary or secondary…
- Trial name
- ACROBATICC (NCT01762813)
- Testing
- open and laparoscopic surgery
- Where
- Norway
- Volunteers
- 1,200 people
- Sponsor
- Helse Stavanger HF
Hepatocellular Carcinoma, Cirrhosis
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
This is a single-site prospective study to describe efficacy endpoints of single agent memantine in patients with unresectable, locally advanced, or metastatic HCC otherwise not deemed candidates for intensive systemic therapy.
- Trial name
- NCT06007846
- Testing
- Namenda
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inova Health Care Services
HCC - Hepatocellular Carcinoma, Conversion Therapy
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
Conversion therapy for unresectable intermediate-advanced hepatocellular carcinoma (uHCC) has evolved from systemic therapy to combined local-systemic approaches, but current regimens still have limited surgical conversion rates.
- Trial name
- NCT07560488
- Testing
- Bevacizumab Biosimilar IBI305, ipilimumab N01, Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer, Gastric Cancer
INSPIRE: a Multi-Cancer Early Detection Study
This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model.
- Conditions
- Lung Cancer, Gastric Cancer, Liver Cancer, Colorectal Cancer
- Trial name
- INSPIRE (NCT06440018)
- Where
- China
- Volunteers
- 5,350 people
- Sponsor
- Singlera Genomics Inc.
Metastatic Colorectal Cancer, Circulating Tumor DNA
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
This is a prospective multicenter cohort study, was designed to explore the prognostic value of ctDNA as a biomarker of disease response and recurrence or death in patients undergoing curative-intent surgical resection of…
- Trial name
- CLIMES (NCT05787197)
- Where
- 16 sites in France
- Volunteers
- 232 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
This phase II trial studies how well selumetinib and Akt inhibitor MK-2206 work in treating patients with refractory or advanced gallbladder or bile duct cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
- Trial name
- NCT01859182
- Testing
- selumetinib, Akt inhibitor MK2206, laboratory biomarker analysis
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Anatomical Radiofrequency Ablation for Small Hepatocellular Carcinoma
The aim of this study is to investigate therapeutic outcomes of anatomical radiofrequency ablation for peripherally located small hepatocellular carcinoma using combined energy delivery mode and triple cooled-wet electrodes.
- Trial name
- NCT05580224
- Testing
- Radiofrequency ablation
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
To determine the Maximum Tolerated Dose (MTD), and the recommended Phase 2 dose of HIA Ipilimumab in combination with IV Nivolumab by monitoring the Dose Limiting Toxicity (DLT) within 1 month after IA Ipilimumab administration…
- Trial name
- HIPANIV (NCT04823403)
- Testing
- Nivolumab, Ipilimumab
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.